Vistagen Therapeutics, Inc. (VTGN:NASDAQ) closed at $0.174 on October 27, 2026, up 0.12% on the day. The stock trades 96.6% below its 52-week high of $5.14 and 2.4% above its 52-week low of $0.170. Over the past year, it lost 95.5%. Vistagen Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 27, 2025, VTGN closed higher on 92 days (37%). Its best day was September 23, 2026 (+48.00%) and its worst was December 17, 2025 (-80.28%). The stock moved 10% or more in a single session 16 times. It opened at least 5% above the previous day's high 2 times.
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing product candidates for patients with central nervous system (CNS) diseases. The company's lead product candidate, AV-101, which is in Phase IIa development as a augmentation option for adult patients suffering from treatment-resistant major depressive disorder (TRD). It also focuses on potential commercial applications of its human pluripotent stem cell (hPSC) technology platform, including drug rescue to develop proprietary small molecule new chemical entities (NCEs) for its internal drug candidate pipeline; and regenerative medicine (RM) using blood, cartilage, heart, and/or liver cells derived from hPSCs. In addition, the company offers CardioSafe 3D, an in vitro cardiac bioassay system for predicting human heart toxicity of small molecule NCEs. It has strategic collaborations with University Health Network, the McEwen Centre for Regenerative Medicine, and the Centre for the Commercialization of Regenerative Medicine for stem cell technology research, development, and cell production; and Norac Pharma, Pharmatek, and Synterys, Inc. to design, produce, and analyze AV...
Find more stocks like VTGN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.